{"transactions":[{"id":672038,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":false,"shares":27584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":137.12,"expiration_date":"2029-08-07","underlying":"Ordinary Shares","underlying_shares":27584},"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672037,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":false,"shares":26116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":113.1,"expiration_date":"2030-02-26","underlying":"Ordinary Shares","underlying_shares":26116},"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672036,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":false,"shares":2916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":137.12,"expiration_date":"2029-08-07","underlying":"Ordinary Shares","underlying_shares":2916},"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672035,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":false,"shares":884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":113.1,"expiration_date":"2030-02-26","underlying":"Ordinary Shares","underlying_shares":884},"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672034,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"sale","planned":true,"acquired":false,"shares":300,"price":252.76,"value":75828.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":65686,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672033,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"sale","planned":true,"acquired":false,"shares":9259,"price":251.9499,"value":2332804.1241,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":65986,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672032,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"sale","planned":true,"acquired":false,"shares":19639,"price":250.6032,"value":4921596.2448,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":75245,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672031,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"sale","planned":true,"acquired":false,"shares":18113,"price":250.0178,"value":4528572.4114,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":94884,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672030,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"sale","planned":true,"acquired":false,"shares":11423,"price":248.6664,"value":2840516.2872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":112997,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672029,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"sale","planned":true,"acquired":false,"shares":18187,"price":247.8573,"value":4507780.7151,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":124420,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672028,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":true,"shares":2916,"price":137.12,"value":399841.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":142607,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672027,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":true,"shares":27584,"price":137.12,"value":3782318.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":139691,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672026,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":true,"shares":884,"price":113.1,"value":99980.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":112107,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":672025,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-08-31T22:45:25.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":true,"shares":26116,"price":113.1,"value":2953719.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":111223,"source":{"system":"sec-edgar","filing":"0001737329-26-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000016/edgardoc.xml","form_type":"4"}},{"id":710619,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-13T20:32:28.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":60000,"derivative":{"exercise_price":1.13,"expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001737329-26-000013","document":"wk-form4_1783974746.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000013/wk-form4_1783974746.xml","form_type":"4"}},{"id":718087,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-07-02T22:16:53.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":3764,"price":237.72,"value":894778.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":85107,"source":{"system":"sec-edgar","filing":"0001737329-26-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000010/edgardoc.xml","form_type":"4"}},{"id":721290,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true}}],"security":"Share Option (Right to Buy)","published_at":"2026-07-01T20:13:08.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Share options vest in twelve equal monthly installments commencing on July 29, 2026."}],"balance_after":47500,"derivative":{"exercise_price":1.61,"expiration_date":"2036-06-29","underlying":"American Depositary Shares","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0001730463-26-000099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173046326000099/form4.xml","form_type":"4"}},{"id":721289,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true}}],"security":"Restricted Share Units","published_at":"2026-07-01T20:13:08.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in one installment on June 29, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in one installment on June 29, 2027."}],"balance_after":31667,"derivative":{"underlying":"American Depositary Shares","underlying_shares":31667},"source":{"system":"sec-edgar","filing":"0001730463-26-000099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173046326000099/form4.xml","form_type":"4"}},{"id":853580,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-03-09T21:21:04.000Z","date":"2026-03-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":6209,"price":188.69,"value":1171576.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":88871,"source":{"system":"sec-edgar","filing":"0001737329-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000006/edgardoc.xml","form_type":"4"}},{"id":874289,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-03-02T22:16:13.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":14822,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":95080,"source":{"system":"sec-edgar","filing":"0001737329-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000004/edgardoc.xml","form_type":"4"}},{"id":934302,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-01-22T00:53:17.000Z","date":"2026-01-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":4140,"price":171.16,"value":708602.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations."}],"balance_after":80258,"source":{"system":"sec-edgar","filing":"0001737329-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000002/edgardoc.xml","form_type":"4"}},{"id":934301,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2026-01-22T00:53:17.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":11699,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance\nattained was certified."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person acquired 71 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025."}],"balance_after":84398,"source":{"system":"sec-edgar","filing":"0001737329-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000002/edgardoc.xml","form_type":"4"}},{"id":993879,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2025-11-20T01:31:34.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":7159,"price":168.26,"value":1204573.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025."}],"balance_after":72628,"source":{"system":"sec-edgar","filing":"0001737329-25-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732925000004/edgardoc.xml","form_type":"4"}},{"id":1209717,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2025-03-12T18:24:35.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":2403,"price":138.4122,"value":332604.5166,"ownership":{"direct":true},"balance_after":79621,"source":{"system":"sec-edgar","filing":"0001765581-25-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558125000035/edgardoc.xml","form_type":"4"}},{"id":1217500,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2025-03-07T23:49:14.000Z","date":"2025-03-07","kind":"sale","planned":true,"acquired":false,"shares":1548,"price":140,"value":216720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":82024,"source":{"system":"sec-edgar","filing":"0001765581-25-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558125000026/edgardoc.xml","form_type":"4"}},{"id":1217499,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2025-03-07T23:49:14.000Z","date":"2025-03-07","kind":"sale","planned":true,"acquired":false,"shares":5532,"price":138.21,"value":764577.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.19 to $138.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":83572,"source":{"system":"sec-edgar","filing":"0001765581-25-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558125000026/edgardoc.xml","form_type":"4"}},{"id":1217498,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D & CMO"}}],"security":"Ordinary Shares","published_at":"2025-03-07T23:49:14.000Z","date":"2025-03-05","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":5239,"price":138.95,"value":727959.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":89104,"source":{"system":"sec-edgar","filing":"0001765581-25-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558125000026/edgardoc.xml","form_type":"4"}},{"id":1235937,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, G R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2025-03-04T01:22:35.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":8859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026."}],"balance_after":94343,"source":{"system":"sec-edgar","filing":"0001765581-25-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558125000020/edgardoc.xml","form_type":"4"}},{"id":1235936,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, G R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2025-03-04T01:22:35.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":17718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":85484,"source":{"system":"sec-edgar","filing":"0001765581-25-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558125000020/edgardoc.xml","form_type":"4"}},{"id":1297713,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, G R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2025-01-22T23:58:14.000Z","date":"2025-01-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":2181,"price":122.62,"value":267434.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations."}],"balance_after":67766,"source":{"system":"sec-edgar","filing":"0001805688-25-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000180568825000013/edgardoc.xml","form_type":"4"}},{"id":1297712,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, G R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2025-01-22T23:58:14.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":7506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person acquired 167 ordinary shares on May 31, 2024 and 48 ordinary shares on November 29, 2024 under a Section 423 Employee Stock Purchase Plan."}],"balance_after":69947,"source":{"system":"sec-edgar","filing":"0001805688-25-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000180568825000013/edgardoc.xml","form_type":"4"}},{"id":1480817,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T20:00:03.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":24200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24200,"derivative":{"exercise_price":16.32,"exercise_date":"2025-06-11","expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":24200},"source":{"system":"sec-edgar","filing":"0000950170-24-073251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017024073251/ownership.xml","form_type":"4"}},{"id":1589232,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D"}}],"security":"Ordinary Shares","published_at":"2024-03-08T02:47:06.000Z","date":"2024-03-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":4294,"price":117.53,"value":504673.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":62226,"source":{"system":"sec-edgar","filing":"0001765581-24-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558124000031/edgardoc.xml","form_type":"4"}},{"id":1596701,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D"}}],"security":"Ordinary Shares","published_at":"2024-03-06T00:47:08.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":16928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":66520,"source":{"system":"sec-edgar","filing":"0001765581-24-000017","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558124000017/edgardoc.xml","form_type":"4"}},{"id":1675291,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D"}}],"security":"Ordinary Shares","published_at":"2024-01-19T23:25:36.000Z","date":"2024-01-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":1730,"price":119.13,"value":206094.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations."}],"balance_after":49592,"source":{"system":"sec-edgar","filing":"0001784606-24-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000178460624000008/edgardoc.xml","form_type":"4"}},{"id":1675290,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D"}}],"security":"Ordinary Shares","published_at":"2024-01-19T23:25:36.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":5970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person acquired 37 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 30, 2023."}],"balance_after":51322,"source":{"system":"sec-edgar","filing":"0001784606-24-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000178460624000008/edgardoc.xml","form_type":"4"}},{"id":1854541,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T19:55:40.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":22383,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22383,"derivative":{"exercise_price":14.77,"exercise_date":"2024-06-13","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":22383},"source":{"system":"sec-edgar","filing":"0001209191-23-037593","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919123037593/doc4.xml","form_type":"4"}},{"id":1863996,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of Research a"}}],"security":"Ordinary Shares","published_at":"2023-06-07T23:16:49.000Z","date":"2023-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1311,"price":129.73,"value":170076.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 137 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2023."}],"balance_after":45315,"source":{"system":"sec-edgar","filing":"0001765581-23-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558123000048/edgardoc.xml","form_type":"4"}},{"id":1904508,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T11:43:59.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":2.8,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001640455-23-000109","document":"wf-form4_168320062719961.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045523000109/wf-form4_168320062719961.xml","form_type":"4"}},{"id":1904507,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T11:43:59.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.27,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000109","document":"wf-form4_168320062719961.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045523000109/wf-form4_168320062719961.xml","form_type":"4"}},{"id":1904506,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T11:43:59.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7850,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.58,"underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0001640455-23-000109","document":"wf-form4_168320062719961.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045523000109/wf-form4_168320062719961.xml","form_type":"4"}},{"id":1904505,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T11:43:59.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent (\"Merger Sub\"), dated as of March 26, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 3, 2023 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.19,"underlying":"Common Stock","underlying_shares":31400},"source":{"system":"sec-edgar","filing":"0001640455-23-000109","document":"wf-form4_168320062719961.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045523000109/wf-form4_168320062719961.xml","form_type":"4"}},{"id":1966122,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of Research a"}}],"security":"Ordinary Shares","published_at":"2023-03-08T02:22:06.000Z","date":"2023-03-05","kind":"tax_withholding","acquired":false,"shares":2274,"price":142.78,"value":324681.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":46489,"source":{"system":"sec-edgar","filing":"0001765581-23-000028","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558123000028/edgardoc.xml","form_type":"4"}},{"id":1966121,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of Research a"}}],"security":"Ordinary Shares","published_at":"2023-03-08T02:22:06.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":12447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":48763,"source":{"system":"sec-edgar","filing":"0001765581-23-000028","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558123000028/edgardoc.xml","form_type":"4"}},{"id":2088057,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D"}}],"security":"Ordinary Shares","published_at":"2022-12-13T22:16:32.000Z","date":"2022-12-09","kind":"sale","acquired":false,"shares":1844,"price":151.54,"value":279439.76,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 51 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022."}],"balance_after":36316,"source":{"system":"sec-edgar","filing":"0001765581-22-000138","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558122000138/edgardoc.xml","form_type":"4"}},{"id":2220206,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T01:05:21.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":20000,"derivative":{"exercise_price":2.8,"expiration_date":"2032-06-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001640455-22-000071","document":"wf-form4_165646470525225.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045522000071/wf-form4_165646470525225.xml","form_type":"4"}},{"id":2236232,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T19:53:42.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":17538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":17538,"derivative":{"exercise_price":18.78,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":17538},"source":{"system":"sec-edgar","filing":"0001209191-22-036139","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036139/doc4.xml","form_type":"4"}},{"id":2239171,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D"}}],"security":"Ordinary Shares","published_at":"2022-06-08T21:01:43.000Z","date":"2022-06-06","kind":"tax_withholding","acquired":false,"shares":1295,"price":149.25,"value":193278.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2022."}],"balance_after":38109,"source":{"system":"sec-edgar","filing":"0001765581-22-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558122000061/edgardoc.xml","form_type":"4"}},{"id":2342037,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D and Ch"}}],"security":"Ordinary Shares","published_at":"2022-03-09T22:54:45.000Z","date":"2022-03-05","kind":"tax_withholding","acquired":false,"shares":1327,"price":153.96,"value":204304.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":39257,"source":{"system":"sec-edgar","filing":"0001765581-22-000019","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558122000019/edgardoc.xml","form_type":"4"}},{"id":2342036,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Head of R&D and Ch"}}],"security":"Ordinary Shares","published_at":"2022-03-09T22:54:45.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":11374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 124 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021."}],"balance_after":40584,"source":{"system":"sec-edgar","filing":"0001765581-22-000019","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558122000019/edgardoc.xml","form_type":"4"}},{"id":2658950,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T20:47:35.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":7.27,"expiration_date":"2031-06-18","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-21-000112","document":"wf-form4_162439483329796.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045521000112/wf-form4_162439483329796.xml","form_type":"4"}},{"id":2661419,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T20:24:30.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":4560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest and become exercisable in full upon the earlier to occur of (a) June 17, 2022 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":4560,"derivative":{"exercise_price":26.03,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":4560},"source":{"system":"sec-edgar","filing":"0000899243-21-025143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000089924321025143/doc4.xml","form_type":"4"}},{"id":2675818,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D, Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-06-09T22:57:13.000Z","date":"2021-06-05","kind":"tax_withholding","acquired":false,"shares":1206,"price":176.47,"value":212822.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28, 2021."}],"balance_after":29086,"source":{"system":"sec-edgar","filing":"0001765581-21-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558121000063/edgardoc.xml","form_type":"4"}},{"id":2733138,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-03T19:09:36.000Z","date":"2021-04-29","kind":"grant","acquired":true,"shares":33217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest over 3 years, with 1/3 vesting on April 29, 2022, and thereafter in equal monthly installments over the next 24 months subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":24.11,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":33217},"source":{"system":"sec-edgar","filing":"0000899243-21-017844","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000089924321017844/doc4.xml","form_type":"4"}},{"id":2800130,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D, Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-10T00:30:46.000Z","date":"2021-03-05","kind":"tax_withholding","acquired":false,"shares":741,"price":164.75,"value":122079.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":30145,"source":{"system":"sec-edgar","filing":"0001765581-21-000036","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558121000036/edgardoc.xml","form_type":"4"}},{"id":2826739,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Ordinary Shares","published_at":"2021-03-01T22:55:23.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":8535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020."}],"balance_after":30886,"source":{"system":"sec-edgar","filing":"0001765581-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558121000020/edgardoc.xml","form_type":"4"}},{"id":3092308,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T23:35:02.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":7850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed on June 29, 2020 erroneously reported 6,775 shares of common stock subject to the stock option. This amendment is being filed to disclose the correct number of shares subject to the reported stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":7850,"derivative":{"exercise_price":7.58,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0001640455-20-000087","document":"wf-form4a_159373288738507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045520000087/wf-form4a_159373288738507.xml","form_type":"4/A","original_submission_date":"2020-06-29"}},{"id":3097659,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-29T23:32:29.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":6775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":6775,"derivative":{"exercise_price":7.58,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":6775},"source":{"system":"sec-edgar","filing":"0001640455-20-000071","document":"wf-form4_159347353043628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045520000071/wf-form4_159347353043628.xml","form_type":"4"}},{"id":3120631,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Ordinary Shares","published_at":"2020-06-06T01:38:24.000Z","date":"2020-06-05","kind":"tax_withholding","acquired":false,"shares":943,"price":120.65,"value":113772.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2020."}],"balance_after":22204,"source":{"system":"sec-edgar","filing":"0001765581-20-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558120000061/edgardoc.xml","form_type":"4"}},{"id":3238413,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-03-02T23:32:56.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":26116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":26116,"derivative":{"exercise_price":113.1,"expiration_date":"2030-02-26","underlying":"Ordinary Shares","underlying_shares":26116},"source":{"system":"sec-edgar","filing":"0001765581-20-000020","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558120000020/edgardoc.xml","form_type":"4"}},{"id":3238412,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2020-03-02T23:32:56.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":884,"derivative":{"exercise_price":113.1,"expiration_date":"2030-02-26","underlying":"Ordinary Shares","underlying_shares":884},"source":{"system":"sec-edgar","filing":"0001765581-20-000020","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558120000020/edgardoc.xml","form_type":"4"}},{"id":3238411,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Ordinary Shares","published_at":"2020-03-02T23:32:56.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":10800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":23000,"source":{"system":"sec-edgar","filing":"0001765581-20-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558120000020/edgardoc.xml","form_type":"4"}},{"id":3304192,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-23T13:08:25.000Z","date":"2020-01-21","kind":"grant","acquired":true,"shares":31400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 21, 2020 and will vest in equal quarterly installments during the twelve quarters following the grant date, subject the to Reporting Person's continued service as a director."}],"balance_after":31400,"derivative":{"exercise_price":7.19,"expiration_date":"2030-01-21","underlying":"Common Stock","underlying_shares":31400},"source":{"system":"sec-edgar","filing":"0001640455-20-000014","document":"wf-form4_157978488746415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000164045520000014/wf-form4_157978488746415.xml","form_type":"4"}},{"id":3441318,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-08-12T20:59:49.000Z","date":"2019-08-08","kind":"grant","acquired":true,"shares":27584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":27584,"derivative":{"exercise_price":137.12,"expiration_date":"2029-08-07","underlying":"Ordinary Shares","underlying_shares":27584},"source":{"system":"sec-edgar","filing":"0001765581-19-000056","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558119000056/edgardoc.xml","form_type":"4"}},{"id":3441317,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2019-08-12T20:59:49.000Z","date":"2019-08-08","kind":"grant","acquired":true,"shares":2916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2916,"derivative":{"exercise_price":137.12,"expiration_date":"2029-08-07","underlying":"Ordinary Shares","underlying_shares":2916},"source":{"system":"sec-edgar","filing":"0001765581-19-000056","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558119000056/edgardoc.xml","form_type":"4"}},{"id":3441316,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Ordinary Shares","published_at":"2019-08-12T20:59:49.000Z","date":"2019-08-08","kind":"grant","acquired":true,"shares":12200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of June 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":12200,"source":{"system":"sec-edgar","filing":"0001765581-19-000056","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000176558119000056/edgardoc.xml","form_type":"4"}},{"id":3591955,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-18T16:39:59.000Z","date":"2019-03-14","kind":"grant","acquired":true,"shares":25660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant."}],"balance_after":25660,"derivative":{"exercise_price":17.94,"expiration_date":"2026-03-14","underlying":"Common Stock, par value $0.01 per share","underlying_shares":25660},"source":{"system":"sec-edgar","filing":"0001104659-19-015617","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919015617/a4.xml","form_type":"4"}},{"id":3591954,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-18T16:39:59.000Z","date":"2019-03-14","kind":"grant","acquired":true,"shares":51230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the \"Plan\"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter."}],"balance_after":51230,"derivative":{"exercise_price":17.94,"expiration_date":"2026-03-14","underlying":"Common Stock, par value $0.01 per share","underlying_shares":51230},"source":{"system":"sec-edgar","filing":"0001104659-19-015617","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919015617/a4.xml","form_type":"4"}},{"id":3813725,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (right to buy)","published_at":"2018-09-18T15:06:15.000Z","date":"2018-09-14","kind":"grant","acquired":true,"shares":15900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and on a quarterly basis thereafter over a three year period."}],"balance_after":15900,"derivative":{"exercise_price":22.27,"exercise_date":"2019-09-14","expiration_date":"2025-09-14","underlying":"Common Stock, par value $0.01 per share","underlying_shares":15900},"source":{"system":"sec-edgar","filing":"0001171843-18-006605","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000117184318006605/ownership.xml","form_type":"4"}}]}